UPDATE: Oppenheimer Initiates Coverage on ANI Pharmaceuticals
January 22, 2014 at 10:54 AM EST
In a report published Wednesday, Oppenheimer analyst Rohit Vanjani initiated coverage on ANI Pharmaceuticals (NASDAQ: ANIP ) with an Outperform rating and $29.00 price target. According to the report, the shares of ANIP are up roughly ~230 percent since its merger with BioSante, largely on the strength of the menopause
